ClinicalTrials.gg
TerminatedNCT03512353Updated Jan 8, 2021Results posted

A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers

A Phase 2 interventional study of Dexamethasone and Carfilzomib in Relapsed or Refractory Multiple Myeloma, sponsored by Amgen. Terminated at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-08.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 381 studies testing dexamethasone in Multiple Myeloma — 44 open to participants now, 104 under way, 14 of them phase 3. Dexamethasone · Multiple Myeloma.

Enrollment
331st of 373
7 · median 45
Started
2018
with 15 others
Phase 2
217 of 381
18 open now
Registered
248th of 381
by date
Lead sponsor
8 of 381
Amgen

Among the 381 studies testing dexamethasone in Multiple Myeloma, this one is the 331st largest by enrollment of the 373 interventional ones that give a count, is one of 16 that started in 2018, is one of 217 in phase 2, and was the 248th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

44 of the 381 studies testing dexamethasone in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

39 more — sign in →

By country, each count listing its studies:

All 44 open studies →

About dexamethasone

Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies testing dexamethasone in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary objective was to describe the safety profile of carfilzomib plus dexamethasone regimen in adults with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy at study entry.

Read the detailed description

This is a phase 2, multicenter, open-label study in adults with RRMM in US community oncology centers. Adults with 1-3 prior lines of therapy at study entry are eligible to be screened for participation. Patients refractory to their last line of treatment are eligible to participate as long as their last line of treatment did not include a proteasome inhibitor (PI). The study will consist of a screening period of up to 28 days for bone marrow assessments and up to 21 days for all other assessments, up to 12 cycles of treatment, and a 30-day safety follow-up period following the last dose of study drug.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 7 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has provided prior to initiation of any study specific activities/procedures.
  • Males or females greater than or equal to 18 years of age.
  • MM after last treatment or refractory while receiving non-proteasome inhibitor therapy.
  • with at least 1 of the following assessed within 21 days prior to enrollment:

    • Immunoglobulin G (IgG) MM: serum monoclonal protein (M-protein) level ≥ 1.0 g/dL
    • IgA, IgD, IgE multiple myeloma: serum M protein level ≥ 0.5 g/dL
    • Urine M-protein ≥ 200 mg per 24 hours
    • In subjects without measurable serum or urine M-protein, serum free light chain (SFLC) ≥ 100 mg/L (involved light chain) and an abnormal serum kappa lambda ratio.
  • Performance Status (ECOG PS) of 0 to 1.
  • Subjects must have at least partial response (PR) to at least 1 .
  • Subjects must have received at least 1 but not more than 3 prior lines of therapy for MM (induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as 1 line of therapy).
  • Prior therapy with a proteasome inhibitor (PI) is allowed as long as the subject had at least a PR to most recent therapy with PI, was not removed due to toxicity (except for neuropathy), did not relapse within 60 days from discontinuation of PI, and will have at least a 6-month PI treatment-free interval from last dose received until enrollment. (Subjects may receive maintenance therapy with drugs that are not PI during this 6-month PI treatment-free interval).

Exclusion criteria

Exclusion Criteria:

  • Waldenström macroglobulinemia.
  • Multiple myeloma of IgM subtype.
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).
  • History of plasma cell leukemia.
  • Primary amyloidosis (patients with multiple myeloma with asymptomatic deposition of amyloid plaques found on would be eligible if all other criteria are met).
  • Subjects with nephrotic range proteinuria (greater than or equal to 3 g albumin for 24 hours urine OR greater than or equal to 2 g albumin/1 g of creatinine on a random urine specimen).
  • Myelodysplastic syndrome.
  • History of other within the past 5 years, with the following exceptions:

    • Malignancy treated with curative intent and with no known active disease present for greater than or equal to 3 years before enrollment and felt to be at low risk for recurrence by the treating physician.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated cervical carcinoma in situ without evidence of disease.
    • Adequately treated breast ductal carcinoma in situ without evidence of disease.
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer.
    • Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.
    • Treated medullary or papillary thyroid cancer.
    • Similar neoplastic conditions with an expectation of greater than 95% five-year disease-free survival.
  • Known (HIV) infection, infection (subjects with hepatitis C that achieve a sustained virologic response following antiviral therapy are allowed), or infection (subjects with hepatitis B surface antigen or core antibody that achieve sustained virologic response with antiviral therapy directed at hepatitis B are allowed).
  • Acute or chronic (any grade).
  • Acute active infection requiring systemic antibiotics, antifungal, antiviral (except antiviral therapy directed at hepatitis B) agents within 14 days prior to enrollment.
  • Known cirrhosis.
  • Significant neuropathy (grades 3 to 4, or grade 2 with pain) within 14 days prior to enrollment.
  • Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to enrollment.
  • Uncontrolled hypertension, defined as an average systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg. Subjects with controlled hypertension are eligible.
  • Hepatic dysfunction within 21 days prior to enrollment: 1.5 times the (ULN) (AST) or alanine aminotransferase (ALT) 3 times the ULN
  • Active congestive heart failure with or without reduced ( [NYHA] Class III to IV), symptomatic ischemia, uncontrolled arrhythmias, (ECG) abnormalities, screening ECG with interval (QTc) of greater than 470 msec, pericardial disease, myocardial infarction within 4 months prior to enrollment.
  • Known .
  • Known interstitial pneumonitis.
  • Immunotherapy within 21 days prior to enrollment.
  • Chemotherapy with approved anticancer therapeutic within 21 days prior to enrollment.
  • therapy (prednisone greater than 30 mg/day or equivalent) within 14 days prior to enrollment.
  • Focal radiation therapy within 7 days prior to enrollment. Radiation therapy to an extended field involving a significant volume of bone marrow within 21 days prior to enrollment (ie, prior radiation must have been to less than 30% of the bone marrow).
  • Major surgery (except kyphoplasty) within 28 days prior to enrollment.
  • or allogeneic stem cell transplant within 90 days prior to enrollment.
  • to dexamethasone.
  • Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib).
  • Intolerance to intravenous (IV) hydration.
  • Currently receiving treatment in another device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
  • Hepatic dysfunction within 21 days prior to enrollment: bilirubin greater than or equal to 1.5 times the upper limit of normal (ULN); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than or equal to 3 times the ULN.
  • Left ventricular ejection fraction less than 40% assessed by transthoracic echocardiogram.
  • Severe valvular disease assessed by transthoracic echocardiogram.
  • Severe right-ventricular dysfunction assessed by transthoracic echocardiogram.
  • Right-ventricular systolic pressure greater than 40 mm Hg assessed by transthoracic echocardiogram.
  • Screening (ANC) should be independent of growth factor support for greater than or equal to 1 week.
  • less than 80 g/L within 21 days prior to enrollment. Use of erythropoietic stimulating factors and red blood cell (RBC) transfusions per institutional guidelines is allowed, however most recent RBC transfusion may not have been done within 7 days prior to obtaining screening hemoglobin.
  • count \< 50 x 10\^9/L (≤ 30 x 10\^9/L if myeloma involvement in the bone marrow is > 50%) within 21 days prior to enrollment. Subjects should not have received platelet transfusions for at least 1 week prior to obtaining the screening platelet count.
  • Estimated (GFR) less than 30 mL/min/1.73 m\^2 (per the Chronic Kidney Disease Epidemiology Collaboration formula) within 21 days prior to enrollment.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Carfilzomib Plus Dexamethasone

    Participants received carfilzomib administered as an intravenous (IV) infusion twice-weekly for up to six 28-day cycles followed by once-weekly for another six 28-day cycles. The carfilzomib dose was 20 mg/m² on days 1 and 2 of cycle 1, 56 mg/m² for the remaining days of cycle 1 (days 8, 9, 15, and 16) and then on days 1, 2, 8, 9, 15, and 16 of each cycle for cycles 2 to 6, and 70 mg/m² on days 1, 8, and 15 of each cycle for cycles 7 to 12. Participants also received dexamethasone either orally or by IV infusion at a dose of 20 mg once daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1 to 6 and at a dose 40 mg once daily on days 1, 8, 15 of cycles 7 to 12.

    Drug: Dexamethasone · Drug: Carfilzomib

Interventions

  • Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.

  • Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All

    Also known as: Kyprolis®

07

What researchers measure

Primary outcomes

  1. Number of Participants Who Completed 12 Cycles of Treatment

    Time frame: 12 cycles (each cycle is 28 days)

  2. Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 12

    Percentage of expected dose of carfilzomib is defined as the percentage of actual cumulative dose (mg/m²) received by the participant relative to the full intended cumulative dose (mg/m²).

    Time frame: Up to 12 cycles (each cycle is 28 days)

  3. Relative Dose Intensity of Carfilzomib in Cycles 1 to 12

    Relative dose intensity = actual dose intensity / planned dose intensity \* 100, where dose intensity is the cumulative dose (mg) divided by the duration of the study drug administration (weeks).

    Time frame: Up to 12 Cycles (each cycle is 28 days)

  4. Number of Participants With Carfilzomib Dose Modifications During Cycles 1 to 12

    Dose modification includes dosage adjustments, delays or discontinuations. A participant is counted only once for a reason category if there were multiple occurrences for the same reason. Participants may be counted in more than one category.

    Time frame: Cycles 1 - 12 (each cycle is 28 days)

  5. Number of Participants With Treatment-emergent Adverse Events

    Treatment-emergent adverse events are defined as any adverse event with an onset date from the first dose through 30 days after the last dose of any study drug. Treatment-emergent related adverse events are adverse events considered related to at least one study drug by the investigator. Adverse events were graded using Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03, where Grade 1: Mild (asymptomatic or mild symptoms) Grade 2: Moderate (minimal, local or noninvasive intervention indicated) Grade 3: Severe (severe) or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated) Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

    Time frame: From the first dose of study drug until 30 days after the last dose (12 months)

Secondary outcomes

  1. Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 6 and 7 to 12

    Percentage of expected dose of carfilzomib is defined as the percentage of actual cumulative dose (mg/m²) received by the participant relative to the full intended cumulative dose (mg/m²).

    Time frame: Cycles 1-6 and 7-12 (each cycle is 28 days)

  2. Relative Dose Intensity of Carfilzomib in Cycles 1 to 6 and 7 to 12

    Relative dose intensity = actual dose intensity / planned dose intensity \* 100, where dose intensity is the cumulative dose (mg) divided by the duration of the study drug administration (weeks).

    Time frame: Cycles 1 - 6 and 7 - 12 (each cycle is 28 days)

  3. Number of Participants With Carfilzomib Dose Modifications During Cycles 1 to 6

    Dose modification includes dosage adjustments, delays or discontinuations. A participant is counted only once for a reason category if there were multiple occurrences for the same reason. Participants may be counted in more than one category.

    Time frame: Cycles 1 - 6 (each cycle is 28 days)

  4. Number of Participants With Carfilzomib Dose Modifications During Cycles 7 to 12

    Dose modification includes dosage adjustments, delays or discontinuations. A participant is counted only once for a reason category if there were multiple occurrences for the same reason. Participants may be counted in more than one category.

    Time frame: Cycles 7 - 12 (each cycle is 28 days)

  5. Number of Participants Who Discontinued Carfilzomib in Cycles 1 to 6 and 7 to 12

    Treatment discontinuation for all reasons in cycles 1 - 6 and cycles 7 - 12

    Time frame: Cycles 1 - 6 and 7 - 12 (each cycle is 28 days)

  6. Change From Baseline to Last Cycle of Treatment in European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Core 30 (C30)

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) is a 30-item questionnaire used to assess the overall quality of life in cancer patients. EORTC QLQ-C30 was administered on day 1 of each treatment cycle. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.

    Time frame: Baseline (cycle 1 day 1) to cycle 12 day 1

  7. Change From Baseline in Average EORTC QLQ-C30 Scores During Cycles 2 to 6 in Participants Who Completed 12 Cycles of Treatment

    EORTC QLQ-C30 was administered on day 1 of each treatment cycle. EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the average score from cycles 2 to 6 and the score on cycle 1 day 1.

    Time frame: Baseline (cycle 1 day 1) and cycles 2 - 6

  8. Change From Cycle 7 Day 1 in Average EORTC QLQ-C30 Scores During Cycles 8 to 12 in Participants Who Completed 12 Cycles of Treatment

    EORTC QLQ-C30 was administered on day 1 of each treatment cycle. EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from baseline indicates an improvement in symptoms. Change was calculated as the difference in the average score from cycles 8 to 12 and the score on cycle 7 day 1.

    Time frame: Cycle 7 day 1 and cycles 8 - 12

  9. Change From Baseline to Last Cycle of Treatment in EORTC QLQ Multiple Myeloma Module (MY-20) Scores

    EORTC QLQ-MY20 is a 20-item questionnaire used in clinical research to assess health-related quality of life in multiple myeloma patients. Questions are answered on a 4-point scale from 1 'Not at All' to 4 'Very Much'. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). Domain scores are calculated as averages and transformed to range from 0 to 100. For the Disease symptoms and side-effects of treatments scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. For the body image and future perspectives scales a higher score represents a higher level of functioning, and a positive change from baseline indicates improvement.

    Time frame: Baseline (cycle 1 day 1) and cycle 12 day 1

  10. Change From Baseline in Average EORTC QLQ-MY20 Scores During Cycles 2 to 6 in Participants Who Completed 12 Cycles of Treatment

    EORTC QLQ-MY20 is a 20-item questionnaire used in clinical research to assess health-related quality of life in multiple myeloma patients. Questions are answered on a 4-point scale from 1 'Not at All' to 4 'Very Much'. The QLQ-MY20 includes four domains (Disease Symptoms, Side-effects of Treatment, Body Image and Future Perspective). Domain scores are calculated as averages and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. For the body image and future perspectives scales a higher score represents a higher level of functioning, and a positive change from baseline indicates improvement. Change from baseline is the difference in the average score from cycles 2 to 6 and the score on cycle 1 day 1.

    Time frame: Baseline (cycle 1 day 1) and cycles 2 - 6

  11. Change From Cycle 7 Day 1 in Average EORTC QLQ-MY20 Scores Over Cycles 8 to 12 in Participants Who Completed 12 Cycles of Treatment

    EORTC QLQ-MY20 is a 20-item questionnaire used in clinical research to assess health-related quality of life in multiple myeloma patients. Questions are answered on a 4-point scale from 1 'Not at All' to 4 'Very Much'. The QLQ-MY20 includes four domains (Disease Symptoms, Side- Effects of Treatment, Body Image and Future Perspective). Domain scores are calculated as averages and transformed to range from 0 to 100. For the disease symptoms and side effects of treatments scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. For the body image and future perspectives scales a higher score represents a higher level of functioning, and a positive change from baseline indicates improvement. Change was calculated as the difference in the average score from cycles 8 to 12 and the score on cycle 7 day 1.

    Time frame: Cycle 7 day 1 and cycles 8 - 12

  12. Overall Response Rate (ORR)

    Disease response and progression were determined using International Myeloma Working Group Uniform Response Criteria (IMWG-URC) 2016, assessed by the Investigator. Per IMWG, determination of disease response requires: serum free light chain (SFLC), serum and urine protein electrophoresis (SPEP, UPEP, respectively), serum and urine immunofixation (SIFE, UIFE, respectively), bone marrow aspirate (for complete response confirmation), corrected calcium (cCa), and plasmacytoma evaluation, if present at screening. Best overall response is defined as a participant's best response during the study. Overall response rate is defined as the percentage of participants achieving a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).

    Time frame: Disease assessments were performed every 28 days up to 12 months from enrollment.

  13. Overall Response Rate (ORR) After 6 Cycles

    Disease response and progression were determined using International Myeloma Working Group Uniform Response Criteria (IMWG-URC) 2016, assessed by the Investigator. Per IMWG, determination of disease response requires: serum free light chain (SFLC), serum and urine protein electrophoresis (SPEP, UPEP, respectively), serum and urine immunofixation (SIFE, UIFE, respectively), bone marrow aspirate (for CR confirmation), corrected calcium, and plasmacytoma evaluation, if present at screening. Overall response rate after 6 cycles is defined as the percentage of participants achieving a best overall response during the first 6 treatment cycles of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).

    Time frame: Disease assessments were performed every 28 days up to 6 cycles of treatment (each cycle was 28 days)

  14. Overall Response Rate (ORR) by Prior Lines of Therapy

    Disease response and progression were determined using International Myeloma Working Group Uniform Response Criteria (IMWG-URC) 2016, assessed by the Investigator. Per IMWG, determination of disease response requires: serum free light chain (SFLC), serum and urine protein electrophoresis (SPEP, UPEP, respectively), serum and urine immunofixation (SIFE, UIFE, respectively), bone marrow aspirate (for CR confirmation), corrected calcium, and plasmacytoma evaluation, if present at screening. Best overall response is defined as a participant's best response during the study. Overall response rate is defined as the percentage of participants achieving a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).

    Time frame: Disease assessments were performed every 28 days up to 12 months from enrollment.

  15. Percentage of Participants With Progression-free Survival (PFS) Events at 12 Months

    Progression-free survival events include disease progression or death due to any cause. Disease progression was determined by the Investigator according to IMWG criteria.

    Time frame: 12 months

  16. Percentage of Participants With PFS Events by Prior Lines of Therapy

    Progression-free survival (PFS) events include disease progression or death due to any cause. Disease progression was determined by the Investigator according to IMWG criteria.

    Time frame: Disease assessments were performed every 28 days up to 12 months from enrollment.

08

Results

Posted Jan 8, 2021
Limitations and caveats
Because of the limited sample size, no meaningful conclusions on the study objectives can be made.

Participant flow

This study was conducted at 10 centers in the United States.

Participant flow — Overall Study
MilestoneCarfilzomib Plus Dexamethasone
Started7
Received treatment6
Completed3
Not completed4
Withdrew: Sponsor decision3
Withdrew: Death1

Outcome measures

PrimaryNumber of Participants Who Completed 12 Cycles of Treatment
Time frame:
12 cycles (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants Who Completed 12 Cycles of Treatment
ParticipantsCarfilzomib Plus Dexamethasone
Number of Participants Who Completed 12 Cycles of Treatment3
PrimaryPercentage of Expected Dose of Carfilzomib Received in Cycles 1 to 12

Percentage of expected dose of carfilzomib is defined as the percentage of actual cumulative dose (mg/m²) received by the participant relative to the full intended cumulative dose (mg/m²).

Time frame:
Up to 12 cycles (each cycle is 28 days)
Reported as:
Mean · percentage of expected dose
Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 12
percentage of expected doseCarfilzomib Plus Dexamethasone
Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 1290.53 ± 9.70
PrimaryRelative Dose Intensity of Carfilzomib in Cycles 1 to 12

Relative dose intensity = actual dose intensity / planned dose intensity \* 100, where dose intensity is the cumulative dose (mg) divided by the duration of the study drug administration (weeks).

Time frame:
Up to 12 Cycles (each cycle is 28 days)
Reported as:
Mean · percentage of dose intensity
Relative Dose Intensity of Carfilzomib in Cycles 1 to 12
percentage of dose intensityCarfilzomib Plus Dexamethasone
Relative Dose Intensity of Carfilzomib in Cycles 1 to 1289.85 ± 11.16
PrimaryNumber of Participants With Carfilzomib Dose Modifications During Cycles 1 to 12

Dose modification includes dosage adjustments, delays or discontinuations. A participant is counted only once for a reason category if there were multiple occurrences for the same reason. Participants may be counted in more than one category.

Time frame:
Cycles 1 - 12 (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Carfilzomib Dose Modifications During Cycles 1 to 12
ParticipantsCarfilzomib Plus Dexamethasone
Any dose modification6
Due to adverse event3
Due to dose administration error1
Per protocol1
Due to weight change2
Due to scheduling issues5
PrimaryNumber of Participants With Treatment-emergent Adverse Events

Treatment-emergent adverse events are defined as any adverse event with an onset date from the first dose through 30 days after the last dose of any study drug. Treatment-emergent related adverse events are adverse events considered related to at least one study drug by the investigator. Adverse events were graded using Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03, where Grade 1: Mild (asymptomatic or mild symptoms) Grade 2: Moderate (minimal, local or noninvasive intervention indicated) Grade 3: Severe (severe) or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated) Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE.

Time frame:
From the first dose of study drug until 30 days after the last dose (12 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsCarfilzomib Plus Dexamethasone
Any adverse event6
Adverse events ≥ Grade 34
Serious adverse events3
Leading to discontinuation of carfilzomib0
Leading to discontinuation of dexamethasone0
Fatal adverse events1
Treatment-related adverse events6
Treatment-related adverse events ≥ Grade 34
Treatment-related serious adverse events3
Treatment-related fatal adverse events1
SecondaryPercentage of Expected Dose of Carfilzomib Received in Cycles 1 to 6 and 7 to 12

Percentage of expected dose of carfilzomib is defined as the percentage of actual cumulative dose (mg/m²) received by the participant relative to the full intended cumulative dose (mg/m²).

Time frame:
Cycles 1-6 and 7-12 (each cycle is 28 days)
Reported as:
Mean · percentage of expected dose
Percentage of Expected Dose of Carfilzomib Received in Cycles 1 to 6 and 7 to 12
percentage of expected doseCarfilzomib Plus Dexamethasone
Cycles 1 - 692.07 ± 8.70
Cycles 7 - 1285.96 ± 12.98
SecondaryRelative Dose Intensity of Carfilzomib in Cycles 1 to 6 and 7 to 12

Relative dose intensity = actual dose intensity / planned dose intensity \* 100, where dose intensity is the cumulative dose (mg) divided by the duration of the study drug administration (weeks).

Time frame:
Cycles 1 - 6 and 7 - 12 (each cycle is 28 days)
Reported as:
Mean · percentage of dose intensity
Relative Dose Intensity of Carfilzomib in Cycles 1 to 6 and 7 to 12
percentage of dose intensityCarfilzomib Plus Dexamethasone
Cycles 1 - 692.80 ± 7.39
Cycles 7 - 1285.96 ± 12.98
SecondaryNumber of Participants With Carfilzomib Dose Modifications During Cycles 1 to 6

Dose modification includes dosage adjustments, delays or discontinuations. A participant is counted only once for a reason category if there were multiple occurrences for the same reason. Participants may be counted in more than one category.

Time frame:
Cycles 1 - 6 (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Carfilzomib Dose Modifications During Cycles 1 to 6
ParticipantsCarfilzomib Plus Dexamethasone
Any dose modification6
Due to adverse event2
Due to dose administration error1
Per protocol1
Due to weight change2
Due to scheduling issues5
SecondaryNumber of Participants With Carfilzomib Dose Modifications During Cycles 7 to 12

Dose modification includes dosage adjustments, delays or discontinuations. A participant is counted only once for a reason category if there were multiple occurrences for the same reason. Participants may be counted in more than one category.

Time frame:
Cycles 7 - 12 (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants With Carfilzomib Dose Modifications During Cycles 7 to 12
ParticipantsCarfilzomib Plus Dexamethasone
Any dose modification4
Due to adverse event3
Due to scheduling issues1
SecondaryNumber of Participants Who Discontinued Carfilzomib in Cycles 1 to 6 and 7 to 12

Treatment discontinuation for all reasons in cycles 1 - 6 and cycles 7 - 12

Time frame:
Cycles 1 - 6 and 7 - 12 (each cycle is 28 days)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Carfilzomib in Cycles 1 to 6 and 7 to 12
ParticipantsCarfilzomib Plus Dexamethasone
Discontinued during cycles 1 - 61
Discontinued during cycles 7 - 122
SecondaryChange From Baseline to Last Cycle of Treatment in European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Core 30 (C30)

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30) is a 30-item questionnaire used to assess the overall quality of life in cancer patients. EORTC QLQ-C30 was administered on day 1 of each treatment cycle. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms.

Time frame:
Baseline (cycle 1 day 1) to cycle 12 day 1
Reported as:
Mean · scores on a scale
Change From Baseline to Last Cycle of Treatment in European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ)-Core 30 (C30)
scores on a scaleCarfilzomib Plus Dexamethasone
Physical Functioning-15.6 ± 15.6
Role Functioning-16.7 ± 25.8
Emotional Functioning-5.6 ± 15.5
Cognitive Functioning2.8 ± 12.6
Social Functioning-19.4 ± 19.5
Fatigue9.3 ± 10.9
Pain-8.3 ± 25.3
Nausea and Vomiting0.0 ± 10.5
Global Health Status-5.6 ± 10.1
Dyspnoea22.2 ± 27.2
Appetite Loss5.6 ± 13.6
Insomnia-5.6 ± 13.6
Constipation11.1 ± 27.2
Diarrhoea-5.6 ± 25.1
Financial Difficulties5.6 ± 13.6
SecondaryChange From Baseline in Average EORTC QLQ-C30 Scores During Cycles 2 to 6 in Participants Who Completed 12 Cycles of Treatment

EORTC QLQ-C30 was administered on day 1 of each treatment cycle. EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from Baseline indicates an improvement in symptoms. Change from baseline is the difference in the average score from cycles 2 to 6 and the score on cycle 1 day 1.

Time frame:
Baseline (cycle 1 day 1) and cycles 2 - 6
Reported as:
Mean · scores on a scale
Change From Baseline in Average EORTC QLQ-C30 Scores During Cycles 2 to 6 in Participants Who Completed 12 Cycles of Treatment
scores on a scaleCarfilzomib Plus Dexamethasone
Physical Functioning-16.9 ± 10.2
Role Functioning-7.8 ± 18.4
Emotional Functioning-13.9 ± 19.5
Cognitive Functioning-4.4 ± 23.7
Social Functioning-12.2 ± 15.8
Fatigue11.9 ± 9.0
Pain-3.3 ± 20.8
Nausea and Vomiting10.0 ± 5.8
Global Health Status-9.4 ± 9.5
Dyspnoea8.9 ± 7.7
Appetite Loss13.3 ± 13.3
Insomnia-11.1 ± 3.9
Constipation-4.4 ± 20.4
Diarrhoea-2.2 ± 16.8
Financial Difficulties6.7 ± 24.0
SecondaryChange From Cycle 7 Day 1 in Average EORTC QLQ-C30 Scores During Cycles 8 to 12 in Participants Who Completed 12 Cycles of Treatment

EORTC QLQ-C30 was administered on day 1 of each treatment cycle. EORTC QLQ-C30 is a 30-item questionnaire used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact). For each of these scales, scores range from 0 to 100. For the GHS and 5 functional scales a high score indicates better global health status/functioning and a positive change from baseline indicates improvement. For the 9 symptom scales, a high score indicates a higher level of symptoms, and a negative change from baseline indicates an improvement in symptoms. Change was calculated as the difference in the average score from cycles 8 to 12 and the score on cycle 7 day 1.

Time frame:
Cycle 7 day 1 and cycles 8 - 12
Reported as:
Mean · scores on a scale
Change From Cycle 7 Day 1 in Average EORTC QLQ-C30 Scores During Cycles 8 to 12 in Participants Who Completed 12 Cycles of Treatment
scores on a scaleCarfilzomib Plus Dexamethasone
Physical Functioning6.2 ± 5.6
Role Functioning-1.1 ± 5.1
Emotional Functioning1.1 ± 1.9
Cognitive Functioning13.3 ± 12.0
Social Functioning0.0 ± 6.7
Fatigue6.7 ± 16.0
Pain13.3 ± 12.0
Nausea and Vomiting6.7 ± 8.8
Global Health Status2.2 ± 1.9
Dyspnoea22.2 ± 13.9
Appetite Loss4.4 ± 7.7
Insomnia4.4 ± 7.7
Constipation0.0 ± 20.0
Diarrhoea-2.2 ± 10.2
Financial Difficulties-4.4 ± 3.9
SecondaryChange From Baseline to Last Cycle of Treatment in EORTC QLQ Multiple Myeloma Module (MY-20) Scores

EORTC QLQ-MY20 is a 20-item questionnaire used in clinical research to assess health-related quality of life in multiple myeloma patients. Questions are answered on a 4-point scale from 1 'Not at All' to 4 'Very Much'. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). Domain scores are calculated as averages and transformed to range from 0 to 100. For the Disease symptoms and side-effects of treatments scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. For the body image and future perspectives scales a higher score represents a higher level of functioning, and a positive change from baseline indicates improvement.

Time frame:
Baseline (cycle 1 day 1) and cycle 12 day 1
Reported as:
Mean · scores on a scale
Change From Baseline to Last Cycle of Treatment in EORTC QLQ Multiple Myeloma Module (MY-20) Scores
scores on a scaleCarfilzomib Plus Dexamethasone
Disease Symptoms-5.6 ± 17.9
Side-effects of Treatment6.5 ± 7.9
Body Image-5.6 ± 13.6
Future Perspective1.9 ± 21.6
SecondaryChange From Baseline in Average EORTC QLQ-MY20 Scores During Cycles 2 to 6 in Participants Who Completed 12 Cycles of Treatment

EORTC QLQ-MY20 is a 20-item questionnaire used in clinical research to assess health-related quality of life in multiple myeloma patients. Questions are answered on a 4-point scale from 1 'Not at All' to 4 'Very Much'. The QLQ-MY20 includes four domains (Disease Symptoms, Side-effects of Treatment, Body Image and Future Perspective). Domain scores are calculated as averages and transformed to range from 0 to 100. For the disease symptoms and side-effects of treatment scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. For the body image and future perspectives scales a higher score represents a higher level of functioning, and a positive change from baseline indicates improvement. Change from baseline is the difference in the average score from cycles 2 to 6 and the score on cycle 1 day 1.

Time frame:
Baseline (cycle 1 day 1) and cycles 2 - 6
Reported as:
Mean · scores on a scale
Change From Baseline in Average EORTC QLQ-MY20 Scores During Cycles 2 to 6 in Participants Who Completed 12 Cycles of Treatment
scores on a scaleCarfilzomib Plus Dexamethasone
Disease Symptoms-13.2 ± 16.4
Side-effects of Treatment10.6 ± 6.8
Body Image-2.8 ± 4.8
Future Perspective6.1 ± 25.3
SecondaryChange From Cycle 7 Day 1 in Average EORTC QLQ-MY20 Scores Over Cycles 8 to 12 in Participants Who Completed 12 Cycles of Treatment

EORTC QLQ-MY20 is a 20-item questionnaire used in clinical research to assess health-related quality of life in multiple myeloma patients. Questions are answered on a 4-point scale from 1 'Not at All' to 4 'Very Much'. The QLQ-MY20 includes four domains (Disease Symptoms, Side- Effects of Treatment, Body Image and Future Perspective). Domain scores are calculated as averages and transformed to range from 0 to 100. For the disease symptoms and side effects of treatments scales a higher score represents a higher level of symptoms/problems and a negative change from baseline value indicates reduction (i.e. improvement) in symptoms. For the body image and future perspectives scales a higher score represents a higher level of functioning, and a positive change from baseline indicates improvement. Change was calculated as the difference in the average score from cycles 8 to 12 and the score on cycle 7 day 1.

Time frame:
Cycle 7 day 1 and cycles 8 - 12
Reported as:
Mean · scores on a scale
Change From Cycle 7 Day 1 in Average EORTC QLQ-MY20 Scores Over Cycles 8 to 12 in Participants Who Completed 12 Cycles of Treatment
scores on a scaleCarfilzomib Plus Dexamethasone
Disease Symptoms8.2 ± 7.6
Side-effects of Treatment-3.8 ± 3.8
Body Image-17.8 ± 20.4
Future Perspective3.0 ± 7.1
SecondaryOverall Response Rate (ORR)

Disease response and progression were determined using International Myeloma Working Group Uniform Response Criteria (IMWG-URC) 2016, assessed by the Investigator. Per IMWG, determination of disease response requires: serum free light chain (SFLC), serum and urine protein electrophoresis (SPEP, UPEP, respectively), serum and urine immunofixation (SIFE, UIFE, respectively), bone marrow aspirate (for complete response confirmation), corrected calcium (cCa), and plasmacytoma evaluation, if present at screening. Best overall response is defined as a participant's best response during the study. Overall response rate is defined as the percentage of participants achieving a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).

Time frame:
Disease assessments were performed every 28 days up to 12 months from enrollment.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsCarfilzomib Plus Dexamethasone
Overall Response Rate (ORR)83.3 (35.9 to 99.6)
SecondaryOverall Response Rate (ORR) After 6 Cycles

Disease response and progression were determined using International Myeloma Working Group Uniform Response Criteria (IMWG-URC) 2016, assessed by the Investigator. Per IMWG, determination of disease response requires: serum free light chain (SFLC), serum and urine protein electrophoresis (SPEP, UPEP, respectively), serum and urine immunofixation (SIFE, UIFE, respectively), bone marrow aspirate (for CR confirmation), corrected calcium, and plasmacytoma evaluation, if present at screening. Overall response rate after 6 cycles is defined as the percentage of participants achieving a best overall response during the first 6 treatment cycles of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).

Time frame:
Disease assessments were performed every 28 days up to 6 cycles of treatment (each cycle was 28 days)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) After 6 Cycles
percentage of participantsCarfilzomib Plus Dexamethasone
Overall Response Rate (ORR) After 6 Cycles83.3 (35.9 to 99.6)
SecondaryOverall Response Rate (ORR) by Prior Lines of Therapy

Disease response and progression were determined using International Myeloma Working Group Uniform Response Criteria (IMWG-URC) 2016, assessed by the Investigator. Per IMWG, determination of disease response requires: serum free light chain (SFLC), serum and urine protein electrophoresis (SPEP, UPEP, respectively), serum and urine immunofixation (SIFE, UIFE, respectively), bone marrow aspirate (for CR confirmation), corrected calcium, and plasmacytoma evaluation, if present at screening. Best overall response is defined as a participant's best response during the study. Overall response rate is defined as the percentage of participants achieving a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR).

Time frame:
Disease assessments were performed every 28 days up to 12 months from enrollment.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) by Prior Lines of Therapy
percentage of participants1 Prior Line of Therapy2+ Prior Lines of Therapy
Overall Response Rate (ORR) by Prior Lines of Therapy75.0 (19.4 to 99.4)100.0 (15.8 to 100.0)
SecondaryPercentage of Participants With Progression-free Survival (PFS) Events at 12 Months

Progression-free survival events include disease progression or death due to any cause. Disease progression was determined by the Investigator according to IMWG criteria.

Time frame:
12 months
Reported as:
Number · percentage of participants
Percentage of Participants With Progression-free Survival (PFS) Events at 12 Months
percentage of participantsCarfilzomib Plus Dexamethasone
Percentage of Participants With Progression-free Survival (PFS) Events at 12 Months50.0
SecondaryPercentage of Participants With PFS Events by Prior Lines of Therapy

Progression-free survival (PFS) events include disease progression or death due to any cause. Disease progression was determined by the Investigator according to IMWG criteria.

Time frame:
Disease assessments were performed every 28 days up to 12 months from enrollment.
Reported as:
Number · percentage of participants
Percentage of Participants With PFS Events by Prior Lines of Therapy
percentage of participants1 Prior Line of Therapy2+ Prior Lines of Therapy
Percentage of Participants With PFS Events by Prior Lines of Therapy50.050.0

Adverse events

Collected over All cause mortality - from enrollment to end of study (13 months) Adverse Events - From the first dose of study drug until 30 days after the last dose (12 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carfilzomib Plus Dexamethasone1/7 (14.3%)3/6 (50%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventCarfilzomib Plus Dexamethasone
Cardiac arrestCardiac disorders1/6
Large intestine perforationGastrointestinal disorders1/6
HyperglycaemiaMetabolism and nutrition disorders1/6
Most frequent other events
Showing 10 of 55
Most frequent other events
EventCarfilzomib Plus Dexamethasone
CoughRespiratory, thoracic and mediastinal disorders4/6
DiarrhoeaGastrointestinal disorders3/6
NauseaGastrointestinal disorders3/6
AnaemiaBlood and lymphatic system disorders2/6
VomitingGastrointestinal disorders2/6
FatigueGeneral disorders2/6
Upper respiratory tract infectionInfections and infestations2/6
Decreased appetiteMetabolism and nutrition disorders2/6
HypokalaemiaMetabolism and nutrition disorders2/6
DizzinessNervous system disorders2/6

Baseline characteristics

The full analysis set includes all enrolled participants who received at least 1 dose of any study treatment (ie, carfilzomib or dexamethasone).

Age, Continuous
Age, Continuous(years)Carfilzomib Plus Dexamethasone
Mean62.5 ± 10.2
Age, Customized
Age, Customized(Participants)Carfilzomib Plus Dexamethasone
18 - 64 years4
65 - 74 years1
≥ 75 years1
Sex: Female, Male
Sex: Female, Male(Participants)Carfilzomib Plus Dexamethasone
Female2
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Carfilzomib Plus Dexamethasone
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Carfilzomib Plus Dexamethasone
Black or African American1
White5
Eastern Cooperative Oncology Group (ECOG) Performance Scale
Eastern Cooperative Oncology Group (ECOG) Performance Scale(Participants)Carfilzomib Plus Dexamethasone
0 (Fully active)5
1 (Restricted but ambulatory)1
2 (Ambulatory but unable to work)0
Number of Prior Treatment Regimens
Number of Prior Treatment Regimens(Participants)Carfilzomib Plus Dexamethasone
1 prior regimen4
2 prior regimens1
3 prior regimens1
09

Study locations

31 sites
  • Research Site
    Palm Springs, California 92262, United States
  • Research Site
    Riverside, California 92501, United States
  • Research Site
    Glenwood Springs, Colorado 81601, United States
  • Research Site
    Boynton Beach, Florida 33426, United States
  • Research Site
    Orange City, Florida 32763, United States
  • Research Site
    Pensacola, Florida 32504, United States
  • Research Site
    Honolulu, Hawaii 96813, United States
  • Research Site
    River Forest, Illinois 60305, United States
  • Research Site
    Tinley Park, Illinois 60487, United States
  • Research Site
    Indianapolis, Indiana 46260, United States
  • Research Site
    Paducah, Kentucky 42003, United States
  • Research Site
    Bethesda, Maryland 20817, United States
  • Research Site
    Midland, Michigan 48640, United States
  • Research Site
    Jackson, Mississippi 39202, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Florham Park, New Jersey 07932, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    Hendersonville, North Carolina 28792, United States
  • Research Site
    Pinehurst, North Carolina 28374, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Zanesville, Ohio 43701, United States
  • Research Site
    Charleston, South Carolina 29414, United States
  • Research Site
    Rock Hill, South Carolina 29732, United States
  • Research Site
    Corpus Christi, Texas 78412, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Houston, Texas 77057, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Ogden, Utah 84405, United States
  • Research Site
    Fredericksburg, Virginia 22408, United States
  • Research Site
    Yakima, Washington 98902, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Jan 2020, 18 months.

Results were first posted in Jan 2021, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2018
First posted
Apr 30, 2018
StartActual
Jul 5, 2018
Primary completionActual
Jan 16, 2020
CompletionActual
Jan 16, 2020
Results first posted
Jan 8, 2021
Last update
Jan 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03512353
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 30, 2018
Start date
Jul 5, 2018
Primary completion
Jan 16, 2020
Completion
Jan 16, 2020
Results posted
Jan 8, 2021
Last update
Jan 8, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexamethasone · Carfilzomib

Start the discussion